导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -2.17% | 3021/4773 |
| 近一周 | 0.87% | 161/5458 |
| 近一月 | 4.72% | 125/5421 |
| 近一季 | 3.41% | 414/5205 |
| 近半年 | -0.89% | 1640/4920 |
| 近一年 | 0.45% | 2706/4361 |
| 近两年 | 28.68% | 2381/2954 |
| 近三年 | 26.26% | 1239/2253 |
| 成立以来 | 199.27% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-4.44% 3628/4961 |
-8.84% 3924/5312 |
- - |
- - |
| 2025 | 8.94% 2887/4813 |
-2.11% 2842/3635 |
7.92% 358/4076 |
-3.43% 3990/4524 |
6.77% 339/4813 |
| 2024 | 29.15% 137/3463 |
8.06% 204/2808 |
4.15% 232/3014 |
13.82% 2099/3129 |
0.82% 1163/3463 |
| 2023 | 0.10% 425/2656 |
2.44% 1350/2280 |
1.49% 213/2385 |
3.90% 166/2515 |
-7.34% 2119/2655 |
| 2022 | -7.71% 147/2207 |
-2.38% 151/1919 |
-0.27% 1612/2016 |
-7.79% 143/2113 |
2.80% 830/2208 |
| 2021 | 5.68% 540/1822 |
5.26% 115/1255 |
-1.33% 1164/1330 |
1.88% 444/1466 |
-0.13% 1203/1822 |
| 2020 | 11.07% 833/1250 |
-10.09% 751/1028 |
3.16% 947/1067 |
11.82% 425/1164 |
7.08% 730/1184 |
| 2019 | 25.44% 600/1092 |
16.09% 676/754 |
1.79% 110/804 |
-1.43% 654/850 |
7.69% 408/918 |
| 2018 | -13.52% 89/834 |
- - |
- - |
- - |
-10.09% 177/691 |
| 2017 | 26.65% 98/714 |
- - |
- - |
- - |
- - |
| 2016 | -1.81% 119/605 |
- - |
- - |
- - |
- - |
| 2015 | 0.70% 249/575 |
- - |
- - |
- - |
- - |
| 2014 | 67.22% 18/237 |
- - |
- - |
- - |
- - |
| 2013 | -9.47% 147/186 |
- - |
- - |
- - |
- - |
| 2012 | 15.34% 12/140 |
- - |
- - |
- - |
- - |
| 2011 | -13.94% 4/102 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 华宝上证180价值ETF联接A VS. 长安沪深300非周期A(740101) |